Myelodysplastic syndromes: Dissecting the heterogeneity

Journal of Clinical Oncology

Volumn 29, Issue 15, 2011, Pages 1937-1938

  Greenberg, Peter L ^a  

^a STANFORD CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LENALIDOMIDE; PROTEIN P53;

5Q- SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; BONE MARROW; CD34 SELECTION; CELL DIFFERENTIATION; CLINICAL FEATURE; CYTOGENETICS; CYTOPENIA; DIAGNOSTIC TEST; EDITORIAL; ERYTHROCYTE TRANSFUSION; GENE EXPRESSION PROFILING; GENETIC SUSCEPTIBILITY; HEMATOPOIETIC CELL; HIGH RISK PATIENT; HUMAN; IMMUNOHISTOCHEMISTRY; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LONG TERM CARE; MYELODYSPLASTIC SYNDROME; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SIGNAL TRANSDUCTION; TELOMERE; TREATMENT OUTCOME; TREATMENT RESPONSE;

CHROMOSOME ABERRATIONS; GENETIC VARIATION; HUMANS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS;

EID: 79956329620     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.2211     Document Type: Editorial

References (15)

1. Greenberg P, Cox C, LeBeau MM, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088, 1997 (Pubitemid 27132124)
2. Cheson BD, Greenberg PL, Bennett JM, et al: Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108:419-425, 2006 (Pubitemid 44061337)
3. Vardiman JW, Thiele J, Arber DA, et al: The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 114:937-951, 2009
4. Malcovati L, Germing U, Kuendgen A, et al: Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25:3503-3510, 2007 (Pubitemid 47315575)
5. Schanz J, Steidl C, Fonatsch C, et al: Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the International Prognostic Scoring System. J Clin Oncol 29:1963-1970, 2011
6. Greenberg P, Tuechler H, Schanz J, et al: Revised International Prognostic Scoring System (IPSS-R), developed by the International Prognostic Working Group for Prognosis in MDS (IWG-PM). Leuk Res (abstr; in press)
7. Mallo M, Cervera J, Schanz J, et al: Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia 25:110-120, 2011
8. Jädersten M, Saft L, Smith A, et al: TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol 29:1971-1989, 2011
9. Ebert BL, Pretz J, Bosco J, et al: Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 451:335-339, 2008
10. Pellagatti A, Marafioti T, Paterson JC, et al: Induction of p53 and upregulation of the p53 pathway in the human 5q- syndrome. Blood 115:2721-2723, 2010
11. Starczynowski DT, Kuchenbauer F, Argiropoulos B, et al: Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nature Med 16:49-58, 2010
12. Sridhar K, Ross DT, Tibshirani R, et al: Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression. Blood 114:4847-4858, 2009
13. Pellagatti A, Cazzola M, Giagounidis A, et al: Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. Leukemia 24:756-764, 2010
14. Jankowska AM, Szpurka H, Tiu RV, et al: Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 113:6403-6410, 2009
15. Lange K, Holm L, Vang Nielsen K, et al: Telomere shortening and chromosomal instability in myelodysplastic syndromes. Genes Chromosomes Cancer 49:260-269, 2010